Finally, the clinical relevance of this work is based on the fact that although RACK1 pharmacological targeting with GCs may be a suitable therapeutic strategy in IBD, particularly in patients with low or no response to GC therapy,92 the novel mechanism of GILZ on RACK1 expression could be considered to improve IBD therapies. Here, RACK1 is linked to inflammatory bowel disease.